A survey has found that there is strong consumer support for pharma manufacturers to disclose the carbon footprint of their medicines, amid rising public scrutiny of the e
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh